Brokerages Expect Agilent Technologies Inc (NYSE:A) Will Post Quarterly Sales of $1.40 Billion

Wall Street brokerages predict that Agilent Technologies Inc (NYSE:A) will post $1.40 billion in sales for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Agilent Technologies’ earnings, with the lowest sales estimate coming in at $1.39 billion and the highest estimate coming in at $1.42 billion. Agilent Technologies posted sales of $1.37 billion in the same quarter last year, which would indicate a positive year over year growth rate of 2.2%. The business is expected to announce its next quarterly earnings report on Monday, November 23rd.

According to Zacks, analysts expect that Agilent Technologies will report full year sales of $5.26 billion for the current year, with estimates ranging from $5.24 billion to $5.28 billion. For the next fiscal year, analysts expect that the company will report sales of $5.63 billion, with estimates ranging from $5.61 billion to $5.69 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Agilent Technologies.

Agilent Technologies (NYSE:A) last announced its earnings results on Tuesday, August 18th. The medical research company reported $0.78 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.66 by $0.12. The company had revenue of $1.26 billion during the quarter, compared to analyst estimates of $1.21 billion. Agilent Technologies had a net margin of 13.23% and a return on equity of 20.57%. Agilent Technologies’s revenue was down .8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.76 earnings per share.

A has been the topic of several analyst reports. UBS Group raised their target price on shares of Agilent Technologies from $84.00 to $87.00 and gave the company a “neutral” rating in a report on Friday, May 22nd. Canaccord Genuity raised their target price on shares of Agilent Technologies from $56.00 to $60.00 and gave the company a “hold” rating in a report on Monday, July 27th. BofA Securities raised their target price on shares of Agilent Technologies from $99.00 to $103.00 and gave the company a “neutral” rating in a report on Wednesday, August 19th. Stifel Nicolaus cut their price objective on shares of Agilent Technologies from $39.00 to $37.00 and set a “hold” rating on the stock in a report on Tuesday, August 25th. Finally, Citigroup raised their price objective on shares of Agilent Technologies from $85.00 to $100.00 and gave the stock a “neutral” rating in a report on Wednesday, August 19th. Fourteen investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $87.05.

In other Agilent Technologies news, VP Rodney Gonsalves sold 6,191 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $98.17, for a total value of $607,770.47. Following the completion of the transaction, the vice president now directly owns 48,334 shares of the company’s stock, valued at $4,744,948.78. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Dominique Grau sold 6,485 shares of the stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $100.00, for a total transaction of $648,500.00. Following the completion of the transaction, the senior vice president now directly owns 104,154 shares of the company’s stock, valued at $10,415,400. The disclosure for this sale can be found here. Over the last quarter, insiders sold 85,392 shares of company stock worth $8,219,555.

A number of institutional investors have recently modified their holdings of the business. State Street Corp increased its stake in shares of Agilent Technologies by 0.4% during the 1st quarter. State Street Corp now owns 13,574,513 shares of the medical research company’s stock worth $974,623,000 after purchasing an additional 50,304 shares in the last quarter. Invesco Ltd. increased its stake in shares of Agilent Technologies by 4.8% during the 1st quarter. Invesco Ltd. now owns 5,018,454 shares of the medical research company’s stock worth $359,422,000 after purchasing an additional 228,244 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Agilent Technologies by 2.0% during the 1st quarter. Geode Capital Management LLC now owns 4,950,997 shares of the medical research company’s stock worth $353,910,000 after purchasing an additional 95,831 shares in the last quarter. Cantillon Capital Management LLC increased its stake in shares of Agilent Technologies by 1.0% during the 2nd quarter. Cantillon Capital Management LLC now owns 4,157,384 shares of the medical research company’s stock worth $367,389,000 after purchasing an additional 42,502 shares in the last quarter. Finally, Viking Global Investors LP purchased a new position in shares of Agilent Technologies during the 1st quarter worth approximately $199,782,000.

NYSE A opened at $99.92 on Thursday. The firm has a 50 day simple moving average of $97.90 and a 200-day simple moving average of $85.41. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.90 and a current ratio of 2.47. Agilent Technologies has a one year low of $61.13 and a one year high of $103.66. The firm has a market cap of $30.65 billion, a price-to-earnings ratio of 45.21, a PEG ratio of 3.08 and a beta of 1.06.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

See Also: What is a Real Estate Investment Trust (REIT)?

Get a free copy of the Zacks research report on Agilent Technologies (A)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply